Market Capitalization

TMSH announces a transformative eyewear deal for its subsidiary, but research reveals the vintage brand's focus was apparel just weeks ago.

Mobile game maker DarkIris pivots to an AI-first strategy, launching an R&D hub in Singapore to build a pan-entertainment AGI content platform.

A SPAC deal aims to list one of America's largest lithium resources on NASDAQ, fueling the high-stakes race for domestic battery minerals.

Activist investor Veradace Partners demands Repay scrap its KUBRA deal, alleging a breach of fiduciary duty and widespread shareholder opposition.

The construction tech firm landed on the 2026 USA TODAY Top Workplaces list. We explore the employee-driven data and culture that set it apart.

As Crocs sets its Q1 earnings call, all eyes are on the struggling HEYDUDE brand, contrasting with the core brand's strong international performance.

ADP's latest dividend declaration highlights its financial strength and commitment to shareholders, cementing its status as a reliable income-generating stock.

As online reviews face a crisis of trust, a Bay Area company doubles down on a physical directory, betting that verified quality is worth its weight in paper.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

With its lead cancer drug advancing and a strong balance sheet, Nurix will detail its vision for protein degradation at a key investor conference.

Computing power operator SAIHEAT is shifting its nuclear strategy from building reactors to selling design software, a bold move into a competitive market.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

A new award-winning serum promises 'glass skin' and enhances injectable results, tapping into a multi-billion dollar market. Here's the science behind it.

Amid claims of undervaluation and AI-driven momentum, the cybersecurity giant escalates its share repurchase plan, signaling deep confidence in its future.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

CanTex Capital's landmark sale of a 1.3M sq ft portfolio to Partners Group highlights booming demand for DFW's strategic shallow bay industrial assets.

A legal battle erupts in Nevada as Getchell Gold Corp. defends its Fondaway Canyon project against a rival's claim on its most valuable ground.

GigaIO sells its core datacenter tech to d-Matrix in a strategic pivot to the booming edge AI market, while d-Matrix gears up to challenge inference giants.

Hycroft Mining announces world-class drill results at its Nevada mine, but a $34M executive compensation package adds a complex layer to the discovery.

The full commercial launch of the Aeros Modular Stem System brings advanced 3D printing and a novel surgical approach to the competitive ankle replacement market.